sur Pentixapharm Holding AG (isin : DE000A40AEG0)
Pentixapharm Reports Third Quarter 2024 Interim Results
Pentixapharm Holding AG has released its interim report for the third quarter of 2024, ending September 30. The company reported a loss of €49k for the period. No revenue was recorded in this stub fiscal year as business operations have not yet started.
The company’s current liabilities stand at €487k, primarily due to the purchase of Pentixapharm AG shares. The spin-off from Eckert & Ziegler SE, scheduled to integrate Pentixapharm AG and Myelo Therapeutics GmbH, was registered after the reporting period.
Pentixapharm anticipates significant fourth-quarter losses, expecting a total loss of around €8 million for the fiscal year. This projection includes results from Pentixapharm AG and Myelo Therapeutics GmbH as of October 2.
The full report is accessible on the company's investor relations website.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Pentixapharm Holding AG